Patient P-02516

Synthetic patientMETA-24 · Day 178 · 45–54 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 68 SC-12 recommended — Supportive Compound SC-12
Day 69 Patient accepted — Started SC-12 in the companion
Day 75 GI symptom burden −23% vs expected — Supportive Compound SC-12
Day 81 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 81 Tolerance state changed — Unstable → Improving
Day 84 ME-01 recommended — Monitoring Escalation ME-01
Day 85 Patient accepted — Started ME-01 in the companion
Day 88 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 81.

Primary contributors, last 14 days

Nutritional resilience-11
Inflammatory activity+9
GI instability+5
Toxicity-3

What helped?

Supportive Compound SC-12Day 68
Result: symptom burden −23%
Monitoring Escalation ME-01Day 84
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
86% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

44 min

improving · +1.8 vs previous 14 d

Sleep duration

Wearable

5.5 h

stable · -0.2 vs previous 14 d

Energy level

Daily log

2.3/10

improving · +0.5 vs previous 14 d

Steps

Wearable

3,930

stable · +24 vs previous 14 d

GI burden

Companion

59.3/100

stable · -1.8 vs previous 14 d

Adherence

Companion

49 %

stable · -0.5 vs previous 14 d

Sleep quality

Wearable

18.3/100

worsening · -2.2 vs previous 14 d

Glucose, CGM daily mean

CGM

151 mg/dL

stable · +1.8 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 29 from the failing basin, 64 from restoration.

Would help

GI-04 GI Support Protocol
74% improved among 66 similar · onset 8 d · confidence 97%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 77%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 77%
More protein
GI -4.9 next day on high-intake days · n 18

Would not help

Keep fat low
GI +4.7 next day on high-intake days · n 29
Keep ultra-processed low
GI +4.4 next day on high-intake days · n 21
Keep alcohol low
GI +4.2 next day on high-intake days · n 20

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-4.9supporter · 95%
Dietary fat load
+4.7detractor · 95%
Ultra-processed food
+4.4detractor · 95%
Alcohol
+4.2detractor · 95%
Simple carbohydrates
+3.5detractor · 95%
Insoluble fibre
+2.8detractor · 85%
Histamine load
-1.1no signal · 28%
Caffeine
+0.7no signal · 16%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Autonomic recovery ↓65
- WearableResting HR 81 bpm
- Wearable3,930 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- WearableSleep 5.5 h, below personal baseline
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 30/100
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 63
Drug metabolism and exposure ↑20
- BloodToxicity index 48

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.3 · butyrate capacity 30/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 5.3 h
Steps: 4,578
Resting HR: 77 bpm

Daily log: GI score 59, nutritional resilience 35, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02483	21%	S06	BR-03	no change	64
P-02087	19%	S01	BR-03	no change	40
P-02025	35%	S15	CR-01	improved	61
P-02009	32%	S08	CR-01	improved	64
P-02054	32%	S01	CR-01	improved	57
P-02151	32%	S04	CR-01	improved	49
P-02154	31%	S16	CR-01	improved	57
P-02233	28%	S16	CR-01	improved	66
P-02395	21%	S12	DT-01	improved	57
P-02274	20%	S15	DT-01	improved	50
P-02339	20%	S03	DT-01	improved	50
P-02491	20%	S09	DT-01	no change	65